Citizens raised its price target on Precigen (PGEN) to $11 from $9, maintaining a Market Outperform rating.
The new target implies a 165% upside from the current price of $4.15.
Analysts increased PAPZIMEOS projections as the launch exceeds expectations. Q1 2026 revenue hit $23.3 million, beating guidance of $18 million and estimates of $19-20 million.
PAPZIMEOS sales reached $21.8 million, ahead of the $19 million estimate.
Citizens raised quarterly projections for 2026. Management noted positive trends continuing into Q2.
The company reiterated cash flow breakeven by year-end 2026.
